IMS Health Capital Report reveals key insights on partnering meeting requests

September 24, 2015 Erin Righetti

IMSHealth_coverIf you have attended an EBD Group partnering event, you have probably wondered which companies from what sector are getting the most attention in the partnering system. We wondered, too, and collaborated with IMS Health Capital, Inc. to produce the report “IMS Health Capital: EBD Partnering Analysis” which was just released prior to BioPharm America 2015 in Boston.

The report analyzed the meeting invitation outcomes from four major partnering conferences: BIO-Europe® 2014 in Frankfurt; BIO-Europe Spring® 2015 in Paris; BioPharm America 2014 in Boston; and Biotech Showcase 2015 in San Francisco.

Sam Murphy of IMS Health Capital Inc. presents the report findings at BioPharm America™ 2015

Sam Murphy of IMS Health Capital Inc. presents the report findings at BioPharm America™ 2015

At BioPharm America last week, Sam Murphy of IMS Health Capital, Inc., gave an overview of their analysis. One finding that is not too surprising is that pharma and biotech companies hold the largest number of meetings across conferences. A few more interesting findings are:

  • Oncology dominates number of invites, but does not stand out in meeting acceptance rate
  • Early-stage assets represent the largest number of meetings overall, but clinical data helps to drive meeting scheduling
  • Phase II invites outnumber Phase I invites, with potential contributions from forward looking positioning and repurposed drugs entering Phase II studies directly
  • Companies that sent a high volume of invites saw a decrease in scheduling success, likely due to the lack of specificity in their outreach

 

These are just a few of the findings. A synopsis of the full report can be found on partnering360® Insight, or you can link to the IMS Health Capital report directly.
For video coverage from BioPharm America 2015, visit partnering360 Insight.

Previous Article
Quintiles: Expanding options for emerging companies
Quintiles: Expanding options for emerging companies

Executives at small, or emerging, biopharmaceutical companies often think their only viable options are to ...

Next Video
BioPharm America™: Interview with Baiju Shah, BioMotiv
BioPharm America™: Interview with Baiju Shah, BioMotiv

Joe Haas from “The Pink Sheet” interviewed Baiju Shah, CEO of BioMotiv, an accelerator of biotechnological ...